Collaborations

Synthetic Vaccine Particles (SVP™) are targeted to interact with immune cells and induce antigen-specific immune responses. SVP are compatible with a wide range of antigens and immunomodulators. The broad applicability and manufacturing scalability that we have demonstrated with our SVP technology platform continues to enable us to engage in collaborations with leading industry organizations.

For further information about Selecta and the company’s collaboration opportunities, please contact bd@selectabio.com.

.

Selecta has in-licensed pegsiticase, a pegylated recombinant uricase from candida utilis from 3SBio. Selecta’s lead product candidate combines pegsiticase with SVP-Rapamycin for the treatment of chronic severe gout, which impacts an estimated 160,000 patients in the U.S. alone.

 

In 2013, Selecta Biosciences was awarded a $1.2 million grant from the Bill and Melinda Gates Foundation to fund the Company’s immune stimulation program for a prophylactic malaria vaccine.  This grant work has been expanded to $1.6 million in total.

Click here to learn more

Selecta is collaborating with the Duke University Medical Center on the potential to utilize SVP-Rapamycin to reduce the immunogenicity of biologic treatments for Pompe disease, which impacts approximately one in 12,000-40,000 people in the United States.

Click here to learn more

Genethon is providing adeno-associated virus (AAV)-based gene therapies and animal models to enable the use of SVP products to mitigate the formation of anti-drug antibodies and to enable repeat administration in gene therapy.

Click here to learn more

The International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, Italy is teaming with Selecta on an SVP-enabled gene therapy candidate for the treatment of Ornithine Transcarbamylase Deficiency (OTC), an inborn error of metabolism affecting approximately one in 15,000-60,000 newborns in the United States.

Click here to learn more

Selecta has in-licensed Anc80, an in silico designed gene therapy vector, from Massachusetts Eye and Ear for the treatment of several diseases, including Methylmalonic Acidemia (MMA), an inborn error of metabolism affecting approximately one in 25,000-48,000 newborns in the United States.

Click here to learn more

Selecta is collaborating with the National Cancer Institute (NCI) on the development of a combination product candidate consisting of LMB-100 and SVP-Rapamycin as a potential treatment for pancreatic cancer, mesothelioma and other cancers.

Click here to learn more

Selecta is teaming with the Venditti laboratory at the National Human Genome Research Institute (NHGRI) on an SVP-enabled gene therapy candidate for the treatment of Melthylmalonic Acidemia (MMA), and inborn error of metabolism affecting approximately one in 25,000-48,000 newborns in the United States.

Click here to learn more

In 2014, Selecta Biosciences was awarded an $8.1 million grant from the National Institute on Drug Abuse (NIDA), an institute within the U.S. National Institutes of Health (NIH), to support research into the development of a next-generation vaccine for smoking cessation and relapse prevention.

Click here to learn more about the award

Click here to learn about our ongoing Phase 1 trial

The Skolkovo Foundation has committed up to $2.7 million in research funding to support Selecta’s development of an immunostimulatory therapeutic SVP to treat human papilloma virus-associated cancers by stimulating the immune system.

Click here to learn more

Back to Top